ImmunityBio, Inc. - 8-K Filing
ImmunityBio signed an exclusive U.S. development and supply agreement with Japan BCG Laboratory for the Tokyo-172 strain of BCG to address a long-standing shortage in the United States, supported by positive Phase III trial results showing non-inferiority versus TICE BCG (hazard ratio 0.82; CI: 0.63–1.08). The agreement grants ImmunityBio exclusive U.S. rights for an initial ten-year term post-FDA approval and positions the company with a second potential supply source alongside its recombinant BCG partnership. (Items: 1.01 Entry into a Material Definitive Agreement, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $IBRX